Prothena Corporation plc PRTA

PRTA Company Overview

Prothena Corporation plc is a clinical-stage biotechnology company focused on the discovery and development of therapies for diseases caused by protein dysregulation and aggregation, particularly neurodegenerative and rare peripheral amyloid diseases. The company operates primarily within the biotechnology and biopharmaceutical industries, with a strategic emphasis on immunology-based approaches and protein biology. Its development programs have targeted conditions such as Alzheimer’s disease, Parkinson’s disease, transthyretin amyloidosis, and other disorders associated with misfolded proteins.

The company’s primary value drivers are its therapeutic candidates, research collaborations, and licensing agreements. Prothena has historically emphasized antibody-based therapies and proprietary platforms related to protein misfolding biology. The company originated as a spinout from Elan Corporation and was established in 2012, later becoming publicly traded on Nasdaq under the ticker PRTA. Its strategic positioning has centered on specialized expertise in amyloid biology and neuroscience-focused drug development, supported by partnerships with larger pharmaceutical companies.